GST-π、TopoⅡ、ER、PR在乳腺癌组织中的表达及其临床意义

Expression and clinical significance of GST-π,TopoⅡ,estrogen and progesterone receptors in breast carcinoma tissues

目的检测谷胱甘肽-S-转移酶-π(GST-π)、DNA拓扑异构酶Ⅱ(TopoⅡ)及雌、孕激素受体(ER、PR)在乳腺癌组织中的表达,分析其在乳腺癌临床病理特征间的关系。方法采用免疫组化方法检测202例未经抗肿瘤治疗的原发性乳腺癌组织中GST-π、TopoⅡ、ER、PR的表达情况。结果乳腺癌组织中TopoⅡ阳性表达率明显高于GST-π、ER、PR的阳性表达率(P<0.05)。GST-π、TopoⅡ的表达与肿瘤的浸润性、临床分期相关;GST-π的表达与腋淋巴结转移有关,与ER、PR呈正相关(P<0.05);GST-π和TopoⅡ之间的表达无相关性(P>0.05)。结论联合检测乳腺癌组织中GST-π、TopoⅡ、ER、PR的表达对乳腺癌治疗方案的制定和预后的判断有重要的参考价值。

Objective To examine the expression of Glutathione -s - transferase -π （GST -π）, Topoisomerase Ⅱ （Topo Ⅱ ）, Estrogen receptor （ER）, Progesterone receptor （PR） in breast carcinoma tissues and study on clinical relationship between GST -π, Topo Ⅱ, ER and PR in breast carcinoma. Methods A total of 202 cases with untreated primary breast carcinoma were detected immunohistochemically for GST - π, Topo Ⅱ , ER and PR. Results The positive expression rate of Topo Ⅱ was much higher than that of GST - π, ER and PR （ P 〈 0.05）. The positive expression rates of GST - π and Topo Ⅱ were correlated with invasive mammary carcinoma and clinical stage （ P 〈0.05）, the positive expression rate of GST - π was correlated with lymph node metastasis and had positive correlation with the expression of ER and PR （ P 〈 0.05）. But there was no relationship between the expression of GST - π and Topo Ⅱ （ P 〉 0.05）. Condusion The expression of GST - π, Topo Ⅱ , ER and PR in breast carcinoma tissues has an instructive significance for leading clinical therapy and for predicting prognosis of patients with breast carcinoma.